Benefix
Manufacturing · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2250 Perimeter Park Dr Ste 300, Morrisvi...Phone Number
(877) 744-5675Revenue
<$5 MillionIndustry
About Benefix
Is Benefix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Benefix has new funding data
Benefix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Benefix had a recent Job posting/layoffs
Product Launch: Get notified when Benefix launches new products
Check if Benefix has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Benefix
Check out if Benefix is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Benefix recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Benefix
Compare insights from companies similar to Benefix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Benefix
Company Profile Activity
Activity Insights
Benefix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Benefix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Benefix.
Benefix Tech Stack
A closer look at the technologies used by Benefix
Benefix News & Media
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). After five years of median follow-up, median progression-free survival (PFS) based on investigator a
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Benefix
Pfizer Hemophilia Connect is a comprehensive support program designed for patients prescribed Pfizer's hemophilia therapies, including HYMPAVZI, XYNTHA, and BeneFix. The program offers resources to help patients navigate insurance coverage, financial assistance, and educational materials related to their treatments. Healthcare providers can also ac... Read More